ArticleJournal of Cancer2026
Association of NAP1L1 polymorphism with clinicopathological progression in oral squamous cell carcinoma.
Article in Journal of Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Nucleosome assembly protein 1-like 1 (NAP1L1) plays an important role in the development and progression of several types of cancer. Subject and Methods: This study investigated the association between NAP1L1 polymorphisms, particularly rs11180813, and susceptibility to oral squamous cell carcinoma (OSCC). Results: Our study showed that betel quid chewing and cigarette smoking were significantly associated with OSCC risk (p < 0.001). No significant correlation was found between NAP1L1 SNPs and overall OSCC susceptibility. However, among OSCC patients, patients with rs11180813 variant genotypes (GC/CC) were associated with lymph node metastasis (adjusted OR = 1.565, 95% CI = 1.042-2.350, p = 0.031) and poor tumor differentiation (adjusted OR = 2.284, 95% CI = 1.126-4.635, p = 0.022). In buccal OSCC, the rs11180813 variant was associated with lymph node metastasis (adjusted OR = 2.349, 95% CI = 1.213-4.549, p = 0.011). TCGA analysis revealed that high NAP1L1 expression correlated significantly with lymph node metastasis and poor tumor differentiation (p < 0.0001). Conclusion: These findings suggest that NAP1L1 and its rs11180813 polymorphism may be associated with certain clinicopathological characteristics of OSCC, particularly lymph node metastasis and tumor differentiation. Further studies are required to validate their clinical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.